These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27920005)

  • 1. Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Dec; 36(12):6699-6703. PubMed ID: 27920005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
    Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
    Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
    Sasaki Y; Nishina T; Yasui H; Goto M; Muro K; Tsuji A; Koizumi W; Toh Y; Hara T; Miyata Y
    Cancer Sci; 2014 Jul; 105(7):812-7. PubMed ID: 24716542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome and Problems of Nab-Paclitaxel Therapy for Gastric Cancer in Clinical Practice].
    Doi T; Ishikawa T; Okayama T; Dohi O; Yoshida N; Kamada K; Katada K; Sogame Y; Uchiyama K; Handa O; Takagi T; Yasuda H; Sakagami J; Konishi H; Naito Y; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):211-4. PubMed ID: 27067684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nanoparticle albumin-bound Paclitaxel for unresectable or recurrent gastric cancer].
    Egawa T; Kemmochi T; Nishiya S; Mihara K; Ito Y; Nagashima A
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2251-3. PubMed ID: 25731486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
    Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
    Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.
    Kanazawa Y; Fujita I; Kakinuma D; Arai H; Matsuno K; Shimoda T; Ko K; Kato S; Uchida E
    Anticancer Res; 2017 May; 37(5):2715-2720. PubMed ID: 28476850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two Cases of Long-Term Control of Advanced Gastric Cancer Treated with>35 Cycles of Low-Dose Nab-Paclitaxel].
    Kawaguchi K; Urayama M; Fujimoto H; Isobe H; Fuse A; Ohta K
    Gan To Kagaku Ryoho; 2019 Oct; 46(10):1569-1572. PubMed ID: 31631141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
    Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
    Aigner J; Marmé F; Smetanay K; Schuetz F; Jaeger D; Schneeweiss A
    Anticancer Res; 2013 Aug; 33(8):3407-13. PubMed ID: 23898112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
    Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
    J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.